Megan Van Etten Megan Van Etten is senior director of public affairs at PhRMA. She is responsible for leading the association’s public affairs efforts on international issues, including trade, intellectual property and access to medicines. Prior to joining PhRMA, Megan was director of media and external communications at the U.S. Chamber of Commerce and communications director at the Beer Institute. She has also worked as a communications consultant for global public relations firms. When not at the office, Megan enjoys exploring new Washington, D.C. restaurants and traveling with her husband and friends.
Recent Posts
What they are saying: Experts highlight the importance of IP in recent NIST proposal comments
By Megan Van Etten | April 20, 2021
Strong, reliable, and clearly defined intellectual property (IP) protections are the foundation of America’s robust innovation ecosystem that patients across the globe rely on for the research and...
Read More
Key excerpts: PhRMA submits comments to NIST in effort to safeguard intellectual property protections
By Megan Van Etten | April 9, 2021
Earlier this week PhRMA submitted comments to the National Institute of Standards and Technology (NIST) regarding the proposed rulemaking on implementing regulations of the Bayh-Dole Act. Passed...
Read More
Building confidence in the COVID-19 vaccine through education
By Megan Van Etten | March 22, 2021
Throughout the COVID-19 vaccine research and development process, the biopharmaceutical industry has worked to uphold the highest standards of research, clinical testing and manufacturing.
Read More
Intellectual property is the key to vaccine development, manufacturing and technology sharing
By Megan Van Etten | March 5, 2021
Earlier today, 31 PhRMA board members signed a letter to President Joe Biden applauding the Administration’s accelerating COVID-19 vaccine rollout, but also warning against efforts to undermine...
Read More
Preserving U.S. innovation worldwide is more important than ever
By Megan Van Etten | January 29, 2021
The COVID-19 pandemic has spurred unprecedented levels of innovation within the biopharmaceutical industry to combat this urgent global health crisis. PhRMA member companies are collaborating with...
Read More
Manufacturing Day 2020: A closer look at the biopharmaceutical industry’s contributions
By Megan Van Etten | October 2, 2020
The first Friday of October marks Manufacturing Day, an annual recognition of the critical role manufacturing industries play in powering innovation and generating jobs and economic growth for...
Read More
IP Explained: Intellectual property system working to combat COVID-19
By Megan Van Etten | May 28, 2020
Biopharmaceutical companies are working around the clock to research and develop COVID-19 vaccines and treatments. Intellectual property (IP) has enabled robust research collaboration among...
Read More
On Manufacturing Day, a closer look at the biopharmaceutical sector’s contributions
By Megan Van Etten | October 4, 2019
Each year, the first Friday in October marks Manufacturing Day, an annual recognition of the critical role manufacturing-intensive industries play in powering innovation and generating jobs and...
Read More
Special 301 submission calls for a level playing field for American innovators
By Megan Van Etten | March 13, 2019
The Office of the U.S. Trade Representative (USTR)’s 2019 Special 301 Report – scheduled to be released this spring – brings critical attention to overseas intellectual property (IP) and market...
Read More
Five myths about global efforts to combat tuberculosis
By Megan Van Etten | September 20, 2018
On September 26, world leaders will convene in New York for the first-ever United Nations (UN) High-Level Meeting on Ending Tuberculosis (TB). This event could not be more critical – or more...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
